The pharmacy discovered an impurity called dimethylformamide, which is classified as a probable carcinogen by the World Health Organization.
The impurity was found in valsartan manufactured by five companies, including Novartis. The online pharmacy recommended a recall.
The FDA will evaluate Valisure’s findings.
Dozens of forms of generic valsartan have been recalled since July 2018, after an impurity known as N-Nitrosodimethylamine was detected in a version of the drug.
Dimethylformamide is the fourth potential carcinogen to be found in generic versions of the heart pills.
More articles on pharmacy:
Lupin recalls 18,408 bottles of antibiotic in US
Bluebird Bio prices gene therapy at $1.8M
10 hospitals seeking pharmacy leaders
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
